AUTHORS
Evan C. Chen, MD, Xiaoqin Yang, PhD2, Mavis Obeng-Kusi, PhD3, Uzor Ogbu, PhD, MBBS4, Rose Chang5, Priyanka Bobbili, MS, ScD6, Louise Clear7, Zhuo Chen8, Yidan Ma9, Tianxiu Li10, Yichuan Grace Hsieh, PhD, RN11, Mei Sheng Duh, ScD, MPH12, Shawn Murphy, MD, PhD13, Gabriela Soriano Hobbs, MD14
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, United States
2 Merck & Co., Inc., Rahway, New Jersey, United States
3 Merck & Co., Inc., Rahway, New Jersey, United States
4 Merck & Co., Inc., Rahway, New Jersey, United States
5 Analysis Group, Boston, Massachusetts, United States
6 Analysis Group, Boston, Massachusetts, United States
7 Analysis Group, Boston, Massachusetts, United States
8 Analysis Group, Boston, Massachusetts, United States
9 Analysis Group, Boston, Massachusetts, United States
10 Analysis Group, Boston, Massachusetts, United States
11 Harvard Medical School, Boston, United States, Mass General Brigham, Somerville, Massachusetts, United States
12 Analysis Group, Boston, Massachusetts, United States
13 Harvard Medical School, Boston, United States, Mass General Brigham, Somerville, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
14 Harvard Medical School, Boston, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
ABSTRACT
Introduction:
Essential thrombocythemia (ET) is a rare myeloproliferative neoplasm characterized by thrombocytosis, vascular complications, and risk of progression to post-ET myelofibrosis (MF) or blast-phase disease. Hydroxyurea (HU) is the most used first-line (1L) cytoreductive therapy; however, a substantial proportion of patients develop resistance or intolerance (R/I) to HU. Limited real-world evidence exists characterizing clinical outcomes among patients with ET who develop HU R/I and those who do not.
Objective:
To compare clinical outcomes between U.S. patients with ET who developed HU R/I and those who did not.
Methods:
Adult patients with ET treated with 1L HU were identified from the Mass General Brigham Research Patient Data Registry (2012–2024). Eligible patients had: (1) ICD-10 ET diagnosis code associated with a hematology/oncology visit; (2) subsequent physician visit with an associated ET diagnosis code; (3) platelet count ≥450×10⁹/L within 6 months before diagnosis, and (4) receipt of 1L HU on or after diagnosis. HU R/I was defined using modified European LeukemiaNet (ELN) criteria as ≥1 of the following while receiving HU: (1) platelet count >400×10⁹/L with WBC <2.5 ×10⁹/L; (2) platelet count >400×10⁹/L with hemoglobin <10g/dL; (3) skin ulcers/sores or other unacceptable mucocutaneous manifestations attributable to HU; or (4) fever attributable to HU. For patients with HU R/I, the index date was the date of first evidence of R/I; for those without R/I, it was imputed based on the distribution of time from 1L HU initiation to first R/I evidence among patients with R/I. Baseline characteristics were assessed during the 6 months before index. 12-month cumulative incidence of clinical outcomes (thrombotic events, major bleeding events, and disease progression to MF or blast phase disease) was assessed from index until the earlier of HU discontinuation or end of follow-up using Kaplan-Meier (KM) methodology. Outcomes were compared between R/I and non-R/I patients using a Cox proportional hazards model adjusted via inverse propensity score weighting (IPTW) for age at treatment initiation, sex, race, high platelet count before 1L HU initiation (>600 × 109/L), high blood pressure (≥ 130/80 mmHg) at baseline, International Prognostic Score of Thrombosis (IPSET) thrombosis risk score, and baseline thrombotic events. IPSET-thrombosis risk score was based on age, history of thrombosis, and JAK2 mutation status.
Results:
Among 634 eligible patients with ET treated with 1L HU, 133 (21.0%) developed HU R/I. Patients with R/I were older at treatment initiation than those without R/I (mean age: 76.9 vs. 71.9 years) and were more frequently White (93.2% vs. 86.8%). The R/I cohort also had a distinct driver mutation profile, with lower JAK2 positivity (62.3% vs. 74.5%) and higher CALR (25.4% vs. 17.0%) and MPL positivity (6.1% vs. 3.9%). Clinically, patients with R/I had a higher proportion of prior thrombotic events (18.8% vs. 12.2%) and high platelet counts before first-line HU initiation (60.2% vs. 46.9%). They were also more likely to have intermediate-risk IPSET-thrombosis scores (20.3% vs. 8.6%), whereas the proportion with high-risk scores was more comparable between cohorts (54.9% vs. 61.7%). The 12-month KM cumulative incidence of thrombotic events was higher among patients with R/I than those without R/I (23.8% vs 15.0%); time-to-thrombotic-event differed (log-rank p<0.05). Patients with R/I also had higher 12-month cumulative incidences of major bleeding events (15.2% vs <4.3%; log-rank p<0.001) and disease progression (<13.3% vs 3.1%; log-rank p<0.05). After IPTW, baseline characteristics were well balanced between the R/I and non-R/I cohorts. In weighted Cox regression, R/I was associated with a higher hazard of thrombotic events (weighted HR 1.60; 95% CI 1.05–2.45; p<0.05). Comparative analyses were not conducted for bleeding events or disease progression due to low event rates.
Conclusions
Among patients with ET receiving 1L HU, approximately one in five developed R/I. Following 1L HU initiation, patients with ET experienced substantial thrombotic, bleeding, and disease progression burden, with significantly higher thrombosis risk among those with R/I as compared to those without. These findings indicate that ET-related complications persist after initiation of HU and that those who develop R/I are at even higher risk, highlighting the need for optimized treatment strategies for this population.
DISCLOSURES
Evan C. Chen, MD: Syndax - Research Funding; Arcellx - Research Funding; Takeda - Research Funding; AbbVie - Research Funding; Merck & Co., Inc. - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony)